Harmonizome 3.0

small ILF3/NF90-associated RNA A13

Predicted to be located in cytoplasm and nucleus. [provided by Alliance of Genome Resources, Mar 2025]

homeobox A13

In vertebrates, the genes encoding the class of transcription factors called homeobox genes are found in clusters named A, B, C, and D on four separate chromosomes. Expression of these proteins is spatially and temporally regulated during embryonic development. This gene is part of the A cluster on chromosome 7 and encodes a DNA-binding transcription factor which may regulate gene expression, morphogenesis, and differentiation. Expansion of a polyalanine tract in the encoded protein can cause hand-foot-uterus syndrome, also known as hand-foot-genital syndrome. [provided by RefSeq, Jul 2008]

S100 calcium binding protein A13

The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a wide range of cells, and involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation. S100 genes include at least 13 members which are located as a cluster on chromosome 1q21. This protein is widely expressed in various types of tissues with a high expression level in thyroid gland. In smooth muscle cells, this protein co-expresses with other family members in the nucleus and in stress fibers, suggesting diverse functions in signal transduction. Multiple alternatively spliced transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008]

ankyrin repeat domain 20 family, member A13, pseudogene

UDP glucuronosyltransferase 1 family, polypeptide A13 pseudogene

annexin A13

This gene encodes a member of the annexin family. Members of this calcium-dependent phospholipid-binding protein family play a role in the regulation of cellular growth and in signal transduction pathways. The specific function of this gene has not yet been determined; however, it is associated with the plasma membrane of undifferentiated, proliferating endothelial cells and differentiated villus enterocytes. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]

melanoma antigen family A13, pseudogene

Predicted to be involved in negative regulation of transcription by RNA polymerase II. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Mar 2025]

family with sequence similarity 90 member A13

From DGIdb Drug Targets 2026

interacting proteins for the A13:B7-24-GG drug from theDGIdb Drug Targets 2026 dataset.

From Allen Brain Atlas Adult Mouse Brain Tissue Gene Expression Profiles

genes with high or low expression in Dopaminergic A13 group relative to other tissues from the Allen Brain Atlas Adult Mouse Brain Tissue Gene Expression Profiles dataset.

From GeneRIF Biological Term Annotations

genes co-occuring with the biological term a13 in literature-supported statements describing functions of genes from the GeneRIF Biological Term Annotations dataset.

From InterPro Predicted Protein Domain Annotations

proteins predicted to have the Protein S100-A13 protein domain from the InterPro Predicted Protein Domain Annotations dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN017_MCF10A.WT.HP_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN017_MCF10A.TP53.M_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN009_HEPG2_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN015_HEPG2_48H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN015_MCF10A.TP53.M_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN012_HEPG2_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN015_MCF10A.WT.HP_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN016_MCF10A.WT.HP_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN008_HEPG2_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN011_HEPG2_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN013_HEPG2_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN014_HEPG2_3H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN015_MCF10A_48H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN016_MCF10A.TP53.M_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN010_HEPG2_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From Carcinogenome Chemical Perturbation Carcinogenicity Signatures

genes differentially expressed following the CRCGN014_HEPG2_24H:A13 small molecule perturbation from the Carcinogenome Chemical Perturbation Carcinogenicity Signatures dataset.

From DGIdb Drug Targets 2026

interacting proteins for the LFM-A13 drug from theDGIdb Drug Targets 2026 dataset.